Enliven Therapeutics, Inc. ((ELVN)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Enliven Therapeutics, Inc. is conducting a clinical study titled ‘A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia.’ The study aims to evaluate the safety and tolerability of ELVN-001, a new drug for patients with chronic myeloid leukemia (CML), particularly those who are resistant or intolerant to existing treatments. The study’s significance lies in its potential to offer a new treatment option for CML patients, especially those with T315I mutations.
The intervention being tested is ELVN-001, an oral drug designed to be taken once or twice daily. It aims to achieve a deep molecular response in CML patients who do not respond well to current therapies.
This interventional study is non-randomized with a sequential intervention model and no masking. Its primary purpose is treatment, focusing on identifying the recommended dose for further clinical evaluation.
The study began on May 22, 2022, and the latest update was submitted on July 15, 2025. These dates are crucial as they mark the study’s progression and ongoing nature.
The update on this study could positively influence Enliven Therapeutics’ stock performance and investor sentiment, as successful results may position ELVN-001 as a competitive option in the CML treatment market. This could also impact competitors who are developing similar therapies.
The study is currently recruiting, with further details available on the ClinicalTrials portal.